VANCOUVER, BC / ACCESSWIRE / April 2, 2024 / Gemina Laboratories Ltd. (CSE:GLAB)(FRA:8I7) (the 'Company' or 'Gemina') is pleased to announce the signing of a license agreement with a significant global diagnostics company. The license agreement is the culmination of Gemina's commercialization program to date and will enable our new licensing partner to develop, manufacture and sell new products using Gemina's IP platform..

不列颠哥伦比亚省温哥华/ACCESSWIRE/2024年4月2日/双子座实验室有限公司（CSE:GLAB）（FRA:8I7）（“公司”或“双子座”）很高兴宣布与一家重要的全球诊断公司签署许可协议。该许可协议是迄今为止双子座商业化计划的高潮，将使我们的新许可合作伙伴能够使用双子座的IP平台开发、制造和销售新产品。。

The agreement is significant for Gemina as it provides a compelling validation of its technology after extensive, detailed scrutiny and evaluation over the last year, by one of the most distinguished players in the $106 billion global in vitro diagnostics market1. Our new partner considers its relationship with Gemina Labs as commercially confidential and has required Gemina to enter into certain confidentiality undertakings.

该协议对双子座来说意义重大，因为它在过去一年中经过了广泛，详细的审查和评估，为其技术提供了令人信服的验证，该公司是全球1060亿美元体外诊断市场上最杰出的参与者之一1。我们的新合作伙伴将其与双子座实验室的关系视为商业机密，并要求双子座签署某些保密承诺。

As a result, we are not currently in a position to identify the counterparty..

因此，我们目前无法确定交易对手。。

Rob Greene Gemina CTO commented, 'Our diagnostic technology asset has passed rigorous testing by one of the best teams in the industry which has resulted in this long-term relationship. We have previously reported how one of our technology breakthroughs saves up to 75% of antibody used on lateral flow tests which could represent a potential $3 billion saving per annum to the lateral flow industry as a whole.

罗布·格林（RobGreeneGemina）首席技术官评论道：“我们的诊断技术资产已经通过了业界最好的团队之一的严格测试，从而形成了这种长期关系。我们之前曾报道过，我们的一项技术突破如何节省高达75%的抗体用于横向流动测试，这可能为整个横向流动行业每年节省30亿美元。

After all our hard work in the lab, we are very pleased to see our technology advance into a first partnership with a market leader that delivers hundreds of millions of tests per annum.'.

经过我们在实验室的辛勤工作，我们非常高兴地看到我们的技术与每年提供数亿次测试的市场领导者建立了首次合作关系。”。

'This is an outstanding first for Gemina,' stated Brian Firth, CEO of Gemina. 'We are now targeting similar licensing deals with strategic partners across the life sciences and medical device sectors to enable next generation diagnostics with our unique suite of proprietary technologies. With antibodies used in lateral flow costing anything up to $1500/mg (30c/test) and Gemina able to achieve dramatic reductions in antibody requirements (and commensurate cost savings), we offer a convincing commercial opportunity for our partners, in multiple segments of the diagnostics market.'.

双子座首席执行官布莱恩·弗斯（BrianFirth）表示，这是双子座的第一次杰出表现我们目前正在与生命科学和医疗器械领域的战略合作伙伴达成类似的许可协议，以利用我们独特的专有技术套件实现下一代诊断。由于横向流动中使用的抗体成本高达1500美元/毫克（30摄氏度/测试），Gemina能够大幅降低抗体需求（并节省相应的成本），我们为我们的合作伙伴在诊断市场的多个领域提供了令人信服的商业机会。”。

[Note 1: Kalorama, Worldwide Market for Diagnostics, 16th Edition]

[注1:Kalorama，《全球诊断市场》，第16版]

On Behalf of the Board of Directors

代表董事会

Brian Firth CEO

Brian Firth首席执行官

Gemina Laboratories Ltd.

Gemina实验室有限公司

About Gemina Laboratories Ltd

关于Gemina Laboratories Ltd

Gemina Labs is a biosensor and diagnostic company with a transformative, patented, proprietary chemistry that powers next generation testing platforms for a wide range of pathogens that affect human health and wellness. Our technology drives testing platforms that are fast, affordable and accurate, and easily self-administered.

双子座实验室（GeminaLabs）是一家生物传感器和诊断公司，拥有一种革命性的专利专有化学物质，为下一代测试平台提供动力，可用于影响人类健康和福祉的多种病原体。我们的技术推动了快速、经济、准确且易于自我管理的测试平台。

Our proprietary product pipeline includes platforms for the rapid testing of COVID-19, influenza, tuberculosis (TB) and other viruses. More information about how Gemina's technology works can be found here https://www.youtube.com/@GeminaLaboratories. Additional information on the Company can be found at www.geminalabs.com..

我们的专有产品线包括用于快速检测COVID-19，流感，结核病（TB）和其他病毒的平台。更多关于双子座技术如何工作的信息可以在这里找到https://www.youtube.com/@双子座实验室。有关该公司的更多信息，请访问www.geminalabs.com。。

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this Release.

加拿大证券交易所及其监管服务提供商（该术语在加拿大证券交易所的政策中定义）均不对本次发布的充分性或准确性承担责任。